ALVOTECH news, videos and press releases - Page 3
For more news please use our advanced search feature.
ALVOTECH - More news...
ALVOTECH - More news...
- Alvotech Appoints Interim Chief Quality Officer
- Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
- Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
- Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
- Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
- Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
- STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
- STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
- Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
- Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
- Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
- Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
- Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
- Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
- STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
- STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
- Alvotech to Present at the Jefferies 2023 London Healthcare Conference
- Alvotech to Present at the Jefferies 2023 London Healthcare Conference
- Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
- Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
- Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland